Intravenous Immunoglobulin Therapy for Gestational Pemphigoid Refractory to Conventional Treatment

Boria, Félix; Maseda, R.; Albízuri, F.; Calle, María de la

doi:10.1016/j.adengl.2020.12.004

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If PG remains refractory to treatment, or prolonged courses of steroids are required, other agents such as intravenous immunoglobulins, dapsone, and azathioprine < 2 mg/kg/day should be considered as steroid-sparing agents [65]. Intravenous immunoglobulins (FDA pregnancy category C) have a good safety profile for the patient and fetus and should be used either in monotherapy or as adjuvant treatment [66][67][68][69][70][71][72][73][74]. Dapsone (FDA pregnancy category C) is also considered safe during gestation.…”

Section: Treatmentmentioning

confidence: 99%

Pruritus in Pregnancy

et al. 2022

View full text Add to dashboard Cite

Pruritus in pregnancy is a common and burdensome symptom that may be a first sign of a pregnancy-specific pruritic disease (atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, and intrahepatic cholestasis in pregnancy) or a dermatosis coinciding with pregnancy by chance. Despite its high prevalence, pruritus is often underrated by physicians, and data regarding the safety profiles of drugs for pruritus are very limited. In this review, we illustrate the epidemiology, possible pathophysiology, clinical characteristics, and diagnostic workup of various pregnancy-related diseases and discuss antipruritic treatments. The prevalence of pruritus in pregnancy demonstrates the importance of symptom recognition and the need for an holistic approach, taking into account both the potential benefits for the patient and the potential risks to the fetus.

show abstract